TF and cancer: The much-studied, plasma membrane-bound form of TF protein termed full-length (fl)TF, is the obligatory cofactor of the plasma serine protease fVIIa and triggers blood clotting either upon tissue damage, or aberrant expression in cells that come in contact with circulating blood; in PDAC, cancer cell-associated and extracellular vesicle-bound flTF both contribute to VTE [2].